How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) announced its earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.06. The company had revenue of $2.20 million for the quarter, compared to analysts' expectations of $2.39 million. Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative trailing twelve-month return on equity of 81.23%. During the same period in the previous year, the firm earned ($0.14) EPS.

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Pfizer (PFE) , AbbVie (ABBV) , AT&T (T) , Idera Pharmaceuticals (IDRA) , OPKO Health (OPK) , SCYNEXIS (SCYX) , Zynerba Pharmaceuticals (ZYNE) and

When did Osmotica Pharmaceuticals IPO?

Osmotica Pharmaceuticals (OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

NASDAQ:OSMT

Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free OSMT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.98
▼
$1.49
52-Week Range: N/A

Volume: 296,500 shs
Average Volume: 396,682 shs
Market Capitalization: $69.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Osmotica Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT)

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

OSMT Stock News Headlines

March 6, 2024 | wsj.com

Vanda Pharmaceuticals Inc.

December 19, 2023 | investing.com

RVL Pharmaceuticals PLC (RVLPQ)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

August 14, 2023 | markets.businessinsider.com

Osmotica Pharmaceuticals is about to announce its earnings — here's what to expect

March 19, 2023 | markets.businessinsider.com

What Wall Street expects from Osmotica Pharmaceuticals's earnings

January 19, 2022 | nz.finance.yahoo.com

GRO Biosciences Appoints Rakhshita Dhar to its Board of Directors

January 19, 2022 | finance.yahoo.com

UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

January 19, 2022 | benzinga.com

Osmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

January 19, 2022 | finance.yahoo.com

Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

January 18, 2022 | finance.yahoo.com

RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

January 6, 2022 | finance.yahoo.com

Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

December 22, 2021 | nasdaq.com

James Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More Shares

December 20, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference

November 17, 2021 | seekingalpha.com

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript

November 17, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals (NASDAQ:OSMT shareholders incur further losses as stock declines 13% this week, taking three-year losses to 78%

November 16, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates

November 15, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

November 15, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021

November 14, 2021 | markets.businessinsider.com

Osmotica Pharmaceuticals earnings: here's what Wall Street expects

November 11, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

November 2, 2021 | finance.yahoo.com

Analysts Estimate Osmotica Pharmaceuticals (OSMT) to Report a Decline in Earnings: What to Look Out for

October 13, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering

October 7, 2021 | msn.com

BRIEF-Osmotica Pharmaceuticals PLC Announces Debt Financing From Athyrium Capital Management Of Up To $100 Mln

October 7, 2021 | marketwatch.com

Osmotica Pharma Shares Drop 37% After Note Purchase Agreement

October 7, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering

October 7, 2021 | finance.yahoo.com

Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering

See More Headlines

Receive OSMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OSMT
CUSIP: N/A
CIK: 1739426
Web: www.osmotica.com
Phone: (908) 809-1300
Fax: N/A
Employees: 302
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-79,590,000.00
Net Margins: -138.76%
Pretax Margin: -167.59%
Return on Equity: -81.23%
Return on Assets: -20.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.43
Quick Ratio: 0.42

Sales & Book Value

Annual Sales: $177.88 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 1.00
Book Value: $1.50 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 62,585,000
Free Float: 59,318,000
Market Cap: $69.47 million
Optionable: Not Optionable
Beta: 2.34

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Brian A. Markison
Chairman & Chief Executive Officer
James Schaub
Chief Operating Officer & Executive Vice President
Andrew J. Einhorn
Chief Financial Officer
Tina Devries
Executive VP-Research & Development
Sergio Alegre
Vice President-Global Compliance

Key Competitors

View All Competitors

OSMT Stock Analysis - Frequently Asked Questions

How were Osmotica Pharmaceuticals' earnings last quarter?: Osmotica Pharmaceuticals plc (NASDAQ:OSMT) announced its earnings results on Monday, November, 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.06. The company had revenue of $2.20 million for the quarter, compared to analysts' expectations of $2.39 million. Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative trailing twelve-month return on equity of 81.23%. During the same period in the previous year, the firm earned ($0.14) EPS.
What other stocks do shareholders of Osmotica Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), AbbVie (ABBV), AT&T (T), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE) and
When did Osmotica Pharmaceuticals IPO?: Osmotica Pharmaceuticals (OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

This page (NASDAQ:OSMT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis

About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT)

OSMT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

OSMT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info